home2023-05-10T10:55:26+02:00

biomarkers for more stability in life

our purpose:
precision
medicine

discovery_and_validation_of_microRNA_biomarkers

TAmiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA - stability for live

our technology:
microRNA
signatures

mircoRNA_signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

TAmiRNA - stability for live

our focus:
age-associated
diseases

age_associated_diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardio-vascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

TAmiRNA - stability for live

biomarkers for more stability in life

our purpose:
precision
medicine

discovery_and_validation_of_microRNA_biomarkers

TamiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology:
microRNA
signatures

mircoRNA_signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

our focus:
age-associated
diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardio-vascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

our products

TAmiRNA - stability for live
TAmiRNA - stability for live
TAmiRNA - stability for live

our products

TAmiRNA - stability for live
TAmiRNA - stability for live
TAmiRNA - stability for live

our services

microRNA services

services

Serum, plasma, urine, saliva, exosomes, cells, and tissues … We provide solutions for your biomarker discovery and validation needs in any biological matrix.

TAmiRNA - the power of microRNA biomarkers

Kit services

Send us your samples to obtain results for osteomiR®, thrombomiR® or toxomiR® biomarkers by taking advantage of our in-house services.

TAmiRNA - the power of microRNA biomarkers
Click_here_for_your_personalized_microRNA_service_offer

our services

microRNA services

services

Serum, plasma, urine, saliva, exosomes, cells, and tissues … We provide solutions for your biomarker discovery and validation needs.

TAmiRNA - the power of microRNA biomarkers

One-Stop-Shop

Obtain results for osteomiR, thrombomiR,and toxomiR biomarkers in your samples by taking advantage of our inhouseservices.

TAmiRNA - the power of microRNA biomarkers
TAmiRNA - stability for live

latest news

TAmiRNA at RNA Leaders conference in Basel

By |March 5th, 2024|Categories: biomarker, biomarkers, microRNAs, NGS|Tags: , , , , , |

TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Basel next week to speak about the recent development of reliable miRNA safety biomarkers and their potential to [...]

Comments Off on TAmiRNA at RNA Leaders conference in Basel

Webinar – COST Action AtheroNET

By |February 13th, 2024|Categories: biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Tags: , , , , , , , , |

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: [...]

Comments Off on Webinar – COST Action AtheroNET

TAmiRNA ‘2023 In Review’

By |January 26th, 2024|Categories: biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Tags: , , , , , , , , , , , , |

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new [...]

Comments Off on TAmiRNA ‘2023 In Review’

TAmiRNA at RNA Leaders conference in Basel

By |March 5th, 2024|Categories: biomarker, biomarkers, microRNAs, NGS|Tags: , , , , , |

TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Basel next week to speak about the recent development of reliable miRNA safety biomarkers and their potential to indicate injury of [...]

Comments Off on TAmiRNA at RNA Leaders conference in Basel

Webinar – COST Action AtheroNET

By |February 13th, 2024|Categories: biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Tags: , , , , , , , , |

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 [...]

Comments Off on Webinar – COST Action AtheroNET

TAmiRNA ‘2023 In Review’

By |January 26th, 2024|Categories: biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Tags: , , , , , , , , , , , , |

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data [...]

Comments Off on TAmiRNA ‘2023 In Review’
Go to Top